NCT07256158

PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma

PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma: a Randomized, Phase III, Non-inferiority studY (PRIORITY Study)

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 518 (estimated)
• Sponsor: Fondazione Italiana Linfomi - ETS · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The final analysis of GHSG HD11 study (not PET driven) showed that 30 Gy IFRT still remains the standard dose after 4 ABVD. Early PET negativity might allow safe radiation de-escalation in patients achieving a metabolic complete response after 2 ABVD. The aim of Priority trial is to explore whether radiotherapy could be safely deescalated to 20 Gy without loss of efficacy in patients treated with four cycles of ABVD who achieved complete metabolic response after the first two cycles.

Conditions

• Hodgkin Lymphoma

Interventions

Type	Name	Description
RADIATION	20 Gy Involved site radiotherapy	Total dose 20 Gy Involved site radiotherapy
RADIATION	30 Gy Involved site radiotherapy	Total dose 30 Gy Involved site radiotherapy

Timeline

• Start date: 2026-03-01
• Primary completion: 2033-03-01
• Completion: 2033-03-01
• First posted: 2025-12-01
• Last updated: 2025-12-09

Locations

38 sites across 1 country: Italy